Phase 3 Study Finds Elagolix Plus Hormone Therapy Combats Heavy Menstrual Bleeding in Uterine Fibroid Patients
News
Results from the Phase 3 ELARIS UF-EXTEND trial show that treatment for a year with elagolix combined with low-dose hormone therapy led to a significant decrease in heavy menstrual bleeding in 87.9 ... Read more